Stacy A. Rudnicki

2.8k total citations
43 papers, 1.1k citations indexed

About

Stacy A. Rudnicki is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Stacy A. Rudnicki has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Neurology, 16 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Stacy A. Rudnicki's work include Amyotrophic Lateral Sclerosis Research (28 papers), Neurogenetic and Muscular Disorders Research (16 papers) and Peripheral Neuropathies and Disorders (5 papers). Stacy A. Rudnicki is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (28 papers), Neurogenetic and Muscular Disorders Research (16 papers) and Peripheral Neuropathies and Disorders (5 papers). Stacy A. Rudnicki collaborates with scholars based in United States, Canada and Italy. Stacy A. Rudnicki's co-authors include Josep Dalmau, Barry W. Festoff, Eseng Lai, Deborah Gelinas, Howard M. Natter, Marek Gawel, R Kratz, Mike Murphy, F. H. Norris and Kevin J. Felice and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and Muscle & Nerve.

In The Last Decade

Stacy A. Rudnicki

40 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stacy A. Rudnicki United States 19 740 395 219 184 116 43 1.1k
Seong‐il Oh South Korea 18 439 0.6× 350 0.9× 181 0.8× 108 0.6× 120 1.0× 66 916
Dieter Heuß Germany 15 506 0.7× 155 0.4× 140 0.6× 179 1.0× 35 0.3× 33 927
Georgios Manousakis United States 12 565 0.8× 275 0.7× 377 1.7× 163 0.9× 23 0.2× 28 1.0k
A Micheli Italy 15 351 0.5× 193 0.5× 201 0.9× 92 0.5× 76 0.7× 27 1.1k
Sharon Nations United States 20 1.5k 2.0× 181 0.5× 122 0.6× 338 1.8× 131 1.1× 37 1.9k
Gaëlle Bruneteau France 25 1.3k 1.8× 817 2.1× 386 1.8× 151 0.8× 77 0.7× 58 1.8k
Valerie Cwik United States 16 345 0.5× 268 0.7× 585 2.7× 179 1.0× 78 0.7× 26 1.1k
Michael Alexander Ireland 17 561 0.8× 367 0.9× 208 0.9× 89 0.5× 189 1.6× 37 1.1k
A. Botturi Italy 18 241 0.3× 330 0.8× 188 0.9× 138 0.8× 43 0.4× 51 965

Countries citing papers authored by Stacy A. Rudnicki

Since Specialization
Citations

This map shows the geographic impact of Stacy A. Rudnicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacy A. Rudnicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacy A. Rudnicki more than expected).

Fields of papers citing papers by Stacy A. Rudnicki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacy A. Rudnicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacy A. Rudnicki. The network helps show where Stacy A. Rudnicki may publish in the future.

Co-authorship network of co-authors of Stacy A. Rudnicki

This figure shows the co-authorship network connecting the top 25 collaborators of Stacy A. Rudnicki. A scholar is included among the top collaborators of Stacy A. Rudnicki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacy A. Rudnicki. Stacy A. Rudnicki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rudnicki, Stacy A., Stuart Kupfer, Fady I. Malik, et al.. (2025). Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 26(7-8). 812–820.
2.
Rudnicki, Stacy A., et al.. (2023). Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 25(3-4). 345–357. 2 indexed citations
3.
Shefner, Jeremy M., Stuart Kupfer, Fady I. Malik, et al.. (2023). Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 25(1-2). 162–169.
4.
Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2023). Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. Journal of Medical Economics. 26(1). 488–493. 2 indexed citations
5.
Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2022). MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(3-4). 304–310. 3 indexed citations
6.
Meng, Lisa, Stacy A. Rudnicki, Noah Lechtzin, et al.. (2019). Correlation between Slow Vital Capacity Measured in the Home and in the Clinic for Patients with Amyotrophic Lateral Sclerosis (P4.4-002). Neurology. 92(15_supplement). 2 indexed citations
7.
Heiman‐Patterson, Terry, Merit Cudkowicz, Mamede de Carvalho, et al.. (2018). Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 19(5-6). 331–341. 34 indexed citations
8.
9.
Jackson, Carlayne E., April McVey, Stacy A. Rudnicki, Mazen M. Dimachkie, & Richard J. Barohn. (2015). Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurologic Clinics. 33(4). 889–908. 35 indexed citations
10.
Rudnicki, Stacy A., et al.. (2015). Is Worse Prognosis in Older ALS Patients More than Just a Matter of Years? (P6.103). Neurology. 84(14_supplement). 2 indexed citations
11.
Gündoğdu, Betül, et al.. (2013). Racial differences in motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 15(1-2). 114–118. 24 indexed citations
12.
Vengoechea, Jaime, et al.. (2013). Clinical variability and female penetrance in X-linked familial FTD/ALS caused by a P506S mutation in UBQLN2. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 14(7-8). 615–619. 27 indexed citations
13.
Rudnicki, Stacy A., et al.. (2012). ALS and Frontotemporal Dysfunction: A Review. Neurology Research International. 2012. 1–9. 47 indexed citations
14.
Rudnicki, Stacy A., James D. Berry, Evan W. Ingersoll, et al.. (2012). Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 14(1). 44–51. 18 indexed citations
15.
El‐Salem, Khalid, et al.. (2011). Prevalence and risk factors of muscle complications secondary to statins. Muscle & Nerve. 44(6). 877–881. 64 indexed citations
16.
Keyrouz, Salah & Stacy A. Rudnicki. (2007). Neuromuscular Involvement in Nephrogenic Systemic Fibrosis. Journal of Clinical Neuromuscular Disease. 9(2). 297–302. 14 indexed citations
17.
Corboy, John R., et al.. (2002). Neurology residency training at the millennium. Neurology. 58(10). 1454–1460. 22 indexed citations
18.
Rudnicki, Stacy A.. (1997). Factors influencing a patient's decision regarding riluzole: an early experience. Journal of the Neurological Sciences. 152. s80–s81. 3 indexed citations
19.
Rudnicki, Stacy A., Francine J. Vriesendorp, Carol Lee Koski, & Richard F. Mayer. (1992). Electrophysiologic studies in the Guillain–Barré syndrome: Effects of plasma exchange and antibody rebound. Muscle & Nerve. 15(1). 57–62. 27 indexed citations
20.
Kozłowski, Piotr, et al.. (1973). [Angiographic appearance of dilated anterior choroid artery in tumors of the central area of the brain].. PubMed. 37(2). 187–95. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seong‐il Oh Breakdown of academic impact, for papers by Dieter Heuß Breakdown of academic impact, for papers by Georgios Manousakis Breakdown of academic impact, for papers by A Micheli Breakdown of academic impact, for papers by Sharon Nations Breakdown of academic impact, for papers by Gaëlle Bruneteau Breakdown of academic impact, for papers by Valerie Cwik Breakdown of academic impact, for papers by Michael Alexander Breakdown of academic impact, for papers by A. Botturi
Rankless by CCL
2026